Navigation Links
Total darkness at night is key to success of breast cancer therapy -- Tulane study
Date:7/24/2014

Exposure to light at night, which shuts off nighttime production of the hormone melatonin, renders breast cancer completely resistant to tamoxifen, a widely used breast cancer drug, says a new study by Tulane University School of Medicine cancer researchers. The study, "Circadian and Melatonin Disruption by Exposure to Light at Night Drives Intrinsic Resistance to Tamoxifen Therapy in Breast Cancer," published in the journal Cancer Research, is the first to show that melatonin is vital to the success of tamoxifen in treating breast cancer.

Principal investigators and co-leaders of Tulane's Circadian Cancer Biology Group, Steven Hill and David Blask, along with team members Robert Dauchy and Shulin Xiang, investigated the role of melatonin on the effectiveness of tamoxifen in combating human breast cancer cells implanted in rats.

"In the first phase of the study, we kept animals in a daily light/dark cycle of 12 hours of light followed by 12 hours of total darkness (melatonin is elevated during the dark phase) for several weeks," says Hill. "In the second study, we exposed them to the same daily light/dark cycle; however, during the 12 hour dark phase, animals were exposed to extremely dim light at night (melatonin levels are suppressed), roughly equivalent to faint light coming under a door."

Melatonin by itself delayed the formation of tumors and significantly slowed their growth but tamoxifen caused a dramatic regression of tumors in animals with either high nighttime levels of melatonin during complete darkness or those receiving melatonin supplementation during dim light at night exposure.

These findings have potentially enormous implications for women being treated with tamoxifen and also regularly exposed to light at night due to sleep problems, working night shifts or exposed to light from computer and TV screens.

"High melatonin levels at night put breast cancer cells to 'sleep' by turning off key growth mechanisms. These cells are vulnerable to tamoxifen. But when the lights are on and melatonin is suppressed, breast cancer cells 'wake up' and ignore tamoxifen," Blask says.

The study could make light at night a new and serious risk factor for developing resistance to tamoxifen and other anticancer drugs and make the use of melatonin in combination with tamoxifen, administered at the optimal time of day or night, standard treatment for breast cancer patients.


'/>"/>

Contact: Arthur Nead
anead@tulane.edu
504-247-1443
Tulane University
Source:Eurekalert  

Related medicine news :

1. NIH scientists take totally tubular journey through brain cells
2. Obesity associated with longer hospital stays, higher costs in total knee replacement patients
3. Patients with metabolic disorder may face higher complication risk following total joint replacement
4. Total hip replacement surgery safe for nonagenarian patients
5. Total Balance Men’s: Review Released for Xtend-Life’s Comprehensive Dietary Supplement for Men
6. Extreme Makeover Home Edition Star John Littlefield Discussed His Experiences on The Show on The Total Education Celebrity Show, a Division of The Simply G Media Network
7. OrthAlign, Inc. Announces Milestone in 13,500th KneeAlign® Total Knee Arthroplasty Case
8. Total Wellness Cleanse Review
9. How This Program Helps People Detox Their Body Naturally – HealthReviewCenter
10. Total Body Cleanse and Detox Tips to Improve Health and Wellness Released by Detox Dieter
11. Total Wellness Cleanse Review Released by Detox Dieter
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Total darkness at night is key to success of breast cancer therapy -- Tulane study
(Date:5/31/2016)... ... 31, 2016 , ... More than 80 representatives of the Hepatitis B ... Cancer Foundation held an event on National Hepatitis Testing Day outside of Philadelphia City ... the leading cause of liver cancer. , Foundation leaders and the citywide coalition they ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... mix of advanced Artificial Intelligence (AI) and the latest in Clinical Patient ... center is integrating predictive analytic outputs directly into the clinical workflow. These insights ...
(Date:5/31/2016)... ... May 31, 2016 , ... Effective leaders not only drive service to the ... whole. On June 2, Northbound CEO Mike Neatherton and COO Paul Alexander will be ... opening plenary on “Leadership: The Journey to Authenticity” with Onsite Workshops CEO Miles Adcock ...
(Date:5/31/2016)... ... 31, 2016 , ... In his latest video, renowned AstroNumerologist ... humans. Using presidential candidate Donald Trump as an example, Kalsi describes the way ... not about adding numbers up,” says Kalsi. “It is about looking at each ...
(Date:5/31/2016)... ... 31, 2016 , ... TeaZa® Energy, LLC announces the launch of ... No Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be available to customers ... , The new flavor is best described as a juicy, taste bud takeover. ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/26/2016)... Since its commercial introduction in ... life science tool for conducting genetic studies in a ... in its new report that the industry sits on ... by a range of new applications in the clinical ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the Human ...
Breaking Medicine Technology: